Published by Avella:
“There has been a great deal of conversation in the healthcare industry recently surrounding direct and indirect remuneration, or “DIR” fees. These fees are charged to pharmacies by Pharmacy Benefit Managers (PBMs), and are causing a dramatic and negative impact to specialty pharmacies and the patients they serve.
This white paper details:
- How criteria for assessing DIR fees is ill-fit for specialty pharmacies
- How specialty pharmacies’ ability to care for vulnerable patients with complex medications is at risk due to these fees
- How exceptionally expensive medication costs are being shifted to patients as a result of DIR fees
- How the US healthcare system and government are also bearing the burden of these fees”